Technology evaluation: ING-1, XOMA.
XOMA is developing ING-1, a human engineered immunoglobulin G1 antibody, as a potential treatment for carcinoma and solid tumors. In November 2000, ING-1 entered phase I trials in the US and by February 2002, phase I/II trials had been initiated.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000378:metabolism; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics / Q000276:immunology*; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006131:Growth Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000379:methods*
D000912:Antibodies, Neoplasm; D015507:Drugs, Investigational; D006131:Growth Inhibitors; D011993:Recombinant Fusion Proteins